Clinical Trial Detail

NCT ID NCT00857389
Title Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements no
Sponsors M.D. Anderson Cancer Center
Indications

non-Hodgkin lymphoma

acute myeloid leukemia

chronic lymphocytic leukemia

bone marrow cancer

acute lymphocytic leukemia

Hodgkin's lymphoma

chronic myeloid leukemia

Therapies

Cyclophosphamide

Filgrastim

Tacrolimus

Thiotepa

anti-thymocyte globulin + Busulfan + Clofarabine

Methotrexate

Age Groups: adult

No variant requirements are available.